Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

The efficacy of temozolomide strongly depends on O(6)-alkylguanine DNA-alkyl transferase (AGAT), which repairs DNA damage caused by the drug itself. Low-dose protracted temozolomide administration can decrease AGAT activity. The main end point of the present study was therefore to test progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandes, A A, Tosoni, A, Cavallo, G, Bertorelle, R, Gioia, V, Franceschi, E, Biscuola, M, Blatt, V, Crinò, L, Ermani, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360560/
https://www.ncbi.nlm.nih.gov/pubmed/17024124
http://dx.doi.org/10.1038/sj.bjc.6603376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360560/
https://www.ncbi.nlm.nih.gov/pubmed/17024124
http://dx.doi.org/10.1038/sj.bjc.6603376

Ejemplares similares